Elanix Biotechnologies AG represents values of innovation, research excellence, and commitment to improving lives through biotechnology. The company focuses on developing advanced regenerative medicine solutions to address pressing medical challenges. Elanix Biotechnologies AG follows a corporate philosophy of integrating cutting-edge scientific advancements into practical applications that benefit patients worldwide. By prioritizing collaboration, ethical standards, and continuous improvement, Elanix Biotechnologies AG strives to be a leading force in the field of biotechnology. Innovating for the future, Elanix Biotechnologies AG is dedicated to making a positive impact on healthcare with its transformative solutions.

Elanix Biotechnologies AG is primarily present in Germany and Switzerland.

Elanix Biotechnologies AG, a renowned company specializing in regenerative medicine, has achieved several significant milestones. Notably, Elanix Biotechnologies AG successfully launched its flagship product, a groundbreaking skin regeneration technology, which has garnered widespread recognition in the industry. The company also achieved an important partnership with a leading global pharmaceutical firm, facilitating the expansion of its innovative solutions to a broader market. Furthermore, Elanix Biotechnologies AG received regulatory approvals for its state-of-the-art products, ensuring compliance with international quality standards and further establishing its position as a leader in the biotechnology sector. These achievements highlight Elanix Biotechnologies AG's commitment to revolutionizing the field of regenerative medicine.

Elanix Biotechnologies AG is a German biotechnology company specializing in regenerative medicine. Established in 2012, the company focuses on developing and commercializing novel cell-based therapies for various skin conditions. With expertise in tissue engineering and cell biology, Elanix Biotechnologies utilizes innovative technology to address unmet medical needs. The company's mission is to improve patients' quality of life through advanced skin regeneration solutions. By leveraging cutting-edge research and strategic partnerships, Elanix Biotechnologies aims to revolutionize the field of dermatology and become a global leader in regenerative medicine.

The main competitors of Elanix Biotechnologies AG in the market include companies such as Organogenesis Holdings Inc., Vericel Corporation, Avita Medical Ltd., and PolarityTE Inc. These companies are active in the field of regenerative medicine and also provide innovative solutions for wound healing and tissue regeneration. However, Elanix Biotechnologies AG distinguishes itself by offering unique products and technologies in the field of skin regeneration, such as its proprietary cell therapy platform. The company's dedication to research and development, strategic partnerships, and global presence helps it maintain a competitive edge in the market.

Elanix Biotechnologies AG is primarily active in the healthcare and biotechnology industries.

The business model of Elanix Biotechnologies AG revolves around advanced regenerative medicine solutions. Elanix specializes in developing and commercializing tissue regeneration therapies to address various medical needs. With a focus on dermatology, Elanix aims to provide innovative and effective treatments for wound healing, skin repair, and skin regeneration. By combining biotechnology and medical expertise, Elanix offers cutting-edge products and technologies that enhance the body's natural regenerative processes. This business model enables Elanix to contribute to the advancement of healthcare, particularly in the field of skin-related conditions, while also driving growth and profitability for the company.

Elanix Biotechnologies için şu anki KGV hesaplanamıyor.

Elanix Biotechnologies için mevcut KUV şu anda hesaplanamıyor.

Elanix Biotechnologies için AlleAktien Kalite Skoru 7/10'dur.

Elanix Biotechnologies için şu an ciro hesaplanamıyor.

Elanix Biotechnologies için şu anda kar hesaplanamıyor.

Elanix Biotechnologies AG is a biotechnology company specializing in the development and marketing of products and services in the field of cell therapy and regenerative medicine. The company is headquartered in Berlin and operates research and development sites in Germany and the USA. The company specializes in three areas of regenerative medicine: tissue regeneration, wound healing, and oncology. In tissue regeneration, Elanix develops cell therapy products for the treatment of skin defects, burns, and wounds. In wound healing, the company develops products to stimulate the healing of complex chronic wounds. In oncology, Elanix focuses on the development of drugs to combat cancer cells. The business model of Elanix is based on the development and marketing of products and services in regenerative medicine. The company's products are typically sold through distribution to hospitals and clinics. Elanix has a well-established network of distribution partners in Europe, the USA, and Asia. In addition to product development and marketing, Elanix also offers services in the field of clinical research and development. The company has an experienced team of scientists and professionals that support clients in the development of new therapeutic approaches. This includes the development of cell therapy products, drug design and development, and the conduct of clinical trials. Elanix Biotechnologies AG's product range includes Ectodex CGB, a cell therapy used for the treatment of burns and skin defects. The company has also developed CombiGel CX, a hydrogel that promotes wound healing and is used for the treatment of chronic wounds. The company is currently working on the development of two additional products: a drug combination for the combination treatment of cancer and a cell therapy for the treatment of hair loss. Overall, Elanix Biotechnologies AG is an emerging biotechnology company with high growth potential due to its wide range of products and services and strong focus on regenerative medicine. The company is well positioned to benefit from the growing opportunities in the field of regenerative medicine, particularly in relation to the increasing demand for genetically modified stem cells and tissue engineering.

Elanix Biotechnologies, yılda kez dağıtılmak üzere 0 EUR tutarında temettü ödemektedir.

Elanix Biotechnologies için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Elanix Biotechnologies şirketinin ISIN kodu DE000A0WMJQ4’dir.

Elanix Biotechnologies 'nin WKN'si A0WMJQ 'dir.

Elanix Biotechnologies için Ticker ELN.F’dir.

Son 12 ay içerisinde Elanix Biotechnologies, 0,40 EUR tutarında bir temettü ödedi. Bu, yaklaşık olarak 754,72 % oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Elanix Biotechnologies, tahmini olarak 0 EUR tutarında bir temettü ödemesi yapacak.

Elanix Biotechnologies şirketinin mevcut temettü verimi 754,72 %.

Elanix Biotechnologies dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Elanix Biotechnologies, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 EUR tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Elanix Biotechnologies, 'Sanayi' sektörüne atanmıştır.

Son Elanix Biotechnologies tarihinde 1,2 EUR tutarındaki en son temettüyü alabilmek için, hisseyi 08.10.1999 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 08.10.1999 olarak gerçekleşti.

2023 yılında Elanix Biotechnologies tarafından 0 EUR olarak temettüler dağıtıldı.

Elanix Biotechnologies hisselerinin temettüleri EUR olarak dağıtılır.